FDA approves a second Alzheimer's drug that can modestly slow disease

The Food and Drug Administration approved Eli Lilly's Kisunla on Tuesday for mild or early cases of dementia caused by Alzheimer'sdrug that can modestly slow the disease, providing a new option for patients in the early stages of the incurable, memory-destroying ailment.approved Eli Lilly's Kisunla on Tuesday for mild or early cases of dementia caused by Alzheimer's.

Both Kisunla and the Japanese drug, Leqembi, are laboratory-made antibodies, administered by IV, that target one contributor to Alzheimer's - sticky amyloid plaque buildup in the brain. Questions remain about which patients should get the drugs and how long they might benefit. The FDA's prescribing information tells doctors they can consider stopping the drug after confirming via brain scans that patients have minimal plaque.

The main safety issue was brain swelling and bleeding, a problem common to all plaque-targeting drugs. The rates reported in Lilly's study - including 20% of patients with microbleeds - were slightly higher than those reported with competitor Leqembi. However, the two drugs were tested in slightly different types of patients, which experts say makes it difficult to compare the drugs' safety.

Health Health Latest News, Health Health Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

High Confidence Alzheimer's Drug Donanemab Will Get FDA Panel NodAn FDA advisory committee will meet June 10 to offer its opinion on whether the agency should greenlight donanemab for Alzheimer's disease.
Source: Medscape - 🏆 386. / 55 Read more »

FDA analysis raises no major concerns about Eli Lilly Alzheimer's drugAn FDA analysis of trial data for Eli Lilly's experimental Alzheimer's drug donanemab released on Thursday revealed no red flags, but raised questions about safety of the treatment for patients with early-stage disease.
Source: KSLcom - 🏆 549. / 51 Read more »

Alzheimer's drug that can slow disease gets backing from FDA advisersFederal health advisers have endorsed a closely watched Alzheimer’s drug from Eli Lilly for people with mild dementia. The FDA will make the final decision on approval later this year. If the agency agrees with its advisers, the drug would only be the second Alzheimer’s drug clearly shown to slow cognitive decline due to Alzheimer’s.
Source: AP - 🏆 728. / 51 Read more »

Alzheimer's drug that can slow disease gets backing from FDA advisersFederal health advisers have endorsed a closely watched Alzheimer’s drug from Eli Lilly for people with mild dementia.
Source: ksatnews - 🏆 442. / 53 Read more »

Lilly's Alzheimer’s drug that can slow disease gets backing from FDA advisersThe Associated Press
Source: NBCNews - 🏆 10. / 86 Read more »